- US-listed companies
- Moderna, Inc.
- Income statement
Moderna, Inc.MRNA
Market cap
$12.5B
P/E ratio
| 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 135 | 60 | 803 | 18,471 | 19,263 | 6,848 | 3,236 |
| Revenue growth (%) | - | ||||||
| Cost of revenue | - | - | 8 | 2,617 | 5,416 | 4,693 | 1,464 |
| Research & development | 454 | 496 | 1,370 | 1,991 | 3,295 | 4,845 | 4,543 |
| Operating margin (%) | |||||||
| Operating income | -413 | -546 | -763 | 13,296 | 9,420 | -4,239 | -3,945 |
| Operating expenses | 548 | 606 | 1,567 | 5,175 | 9,843 | 11,087 | 7,181 |
| Income before tax | -384 | -515 | -745 | 13,285 | 9,575 | -3,942 | -3,607 |
| Pretax margin (%) | -284.6 | -854.9 | -92.7 | 71.9 | 49.7 | -57.6 | -111.5 |
| Provision for income taxes | 0 | -1 | 3 | 1,083 | 1,213 | 772 | -46 |
| Effective tax rate (%) | |||||||
| Net income | -385 | -514 | -747 | 12,202 | 8,362 | -4,714 | -3,561 |
| Net income margin (%) | |||||||
| Earnings per share | - | - | - | 30.31 | 21.26 | -12.33 | -9.28 |
| Diluted EPS | - | - | - | 28.29 | 20.12 | -12.33 | -9.28 |
| EBITDA | - | - | |||||
| EBITDA margin (%) | - | - |